Results 131 to 140 of about 28,823 (297)
Heart Failure and Dipeptidyl Peptidase-4 Inhibitors [PDF]
European Journal of Heart Failure, 2014 Henry, Krum +3 more
openaire +2 more sources
Isolation and characterization of Dipeptidyl Peptidase IV from human placenta [PDF]
, 2010 Human placenta is surprisingly rich in post-proline dipeptidyl peptidase activity. Among various cell fractions, microsomes have the highest specific activity. A homogeneous enzyme preparation is obtained in a six-step purification procedure.
Heymann, Eberhard +2 more
core
Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux +14 more
wiley +1 more source
Saxagliptin for type 2 diabetes
Diabetes, Metabolic Syndrome and Obesity, 2010 Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients ...
Chacra
doaj +2 more sources
Structure-based discovery of dipeptidyl peptidase IV inhibitors [PDF]
Structure-based discovery of dipeptidyl peptidase IV inhibitors. Diabetes afflicts approximately 151 million people worldwide, with an estimated increase to 221 million by 2010.
core
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier +4 more
wiley +1 more source
D-420720, A Novel Orally Active Sulfonamide Compound Dipeptidyl Peptidase IV Inhibitor: Structure and Activity Relationship of Arylsuffonamide to Dipeptidyl Peptidase IV Inhibition [PDF]
, 2010 [[abstract]]Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that requires constant monitoring and adjustment of blood glucose levels by exogenous intervention.
Tsai, HJ (Tsai, Henry J.); Chou, SY (Chou, Shan-Yen); Chuang, SH (Chuang, Shih-Hsien); Chen, CC (Chen, Chien-Cheng); Hsu, FL (Hsu, Feng-Lin)
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We
Hong Sang Choi +7 more
wiley +1 more source
Dipeptidyl Peptidase 4 Inhibitor, an Update [PDF]
The Journal of Korean Diabetes, 2021 openaire +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims This study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. Materials and Methods Australian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of ...
Peter S. Hamblin +5 more
wiley +1 more source